Cargando…
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
BACKGROUND: Upregulation of human epidermal growth factor receptor 3 (HER3) is a major mechanism of acquired resistance to therapies targeting its heterodimerization partners epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), but also exposes HER3 as a targe...
Autores principales: | Osada, Takuya, Hartman, Zachary C., Wei, Junping, Lei, Gangjun, Hobeika, Amy C., Gwin, William R., Diniz, Marcio A., Spector, Neil, Clay, Timothy M., Chen, Wei, Morse, Michael A., Lyerly, H. Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085609/ https://www.ncbi.nlm.nih.gov/pubmed/30092835 http://dx.doi.org/10.1186/s13058-018-1023-x |
Ejemplares similares
-
Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013) -
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2012) -
HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
por: Chen, Alan Chen, et al.
Publicado: (2020) -
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
por: Ren, Xiu-Rong, et al.
Publicado: (2012) -
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)